Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model

Molecular Medicine Reports

Volumn 11, Issue 3, 2015, Pages 1693-1700

  Douhara, Akitoshi ^a   Moriya, Kei ^a   Yoshiji, Hitoshi ^a   Noguchi, Ryuichi ^a   Namisaki, Tadashi ^a   Kitade, Mitsuteru ^a   Kaji, Kosuke ^a   Aihara, Yosuke ^a   Nishimura, Norihisa ^a   Takeda, Kosuke ^a   Okura, Yasushi ^a   Kawaratani, Hideto ^a   Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Endotoxin; Hepatic stellate cell; Intestinal permeability; Liver fibrosis; Non alcoholic steatohepatitis; Toll like receptor 4

Indexed keywords

CLAUDIN 4; COLLAGEN TYPE 1; DRINKING WATER; ENDOTOXIN; LIPOPOLYSACCHARIDE BINDING PROTEIN; MESSENGER RNA; NEOMYCIN; POLYMYXIN B; PROTEIN ZO1; TIGHT JUNCTION PROTEIN; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; ANTIINFECTIVE AGENT; LIPOPOLYSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CORRELATION ANALYSIS; EXPERIMENTAL LIVER FIBROSIS; FIBROGENESIS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTESTINE MUCOSA PERMEABILITY; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION; RAT; REMISSION; SIGNAL TRANSDUCTION; STELLATE CELL; VITAMIN DEFICIENCY; ANIMAL; ANIMAL FOOD; COMPLICATION; DRUG EFFECTS; INTESTINE; LIVER CIRRHOSIS; METABOLISM; PERMEABILITY;

ANIMALIA; BACTERIA (MICROORGANISMS); RATTUS;

ANIMAL FEED; ANIMALS; ANTI-BACTERIAL AGENTS; ENDOTOXINS; HEPATIC STELLATE CELLS; INTESTINES; LIPOPOLYSACCHARIDES; LIVER CIRRHOSIS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; PERMEABILITY; RATS; SIGNAL TRANSDUCTION; TIGHT JUNCTION PROTEINS; TOLL-LIKE RECEPTOR 4;

EID: 84916608629     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2995     Document Type: Article

References (30)

1. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231, 2002.
2. Henao-Mejia J, Elinav E, Jin C, et al: Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482: 179-185, 2012.
3. Ekstedt M, Franzen LE, Mathiesen UL, et al: Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44: 865-873, 2006.
4. El-Serag HB: Hepatocellular carcinoma. N Engl J Med 365: 1118-1127, 2011.
5. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M and Wallace M: Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 47: 571-579, 2007.
6. Akira S and Takeda K: Toll-like receptor signaling. Nat Rev Immunol 4: 499-511, 2004.
7. Jagavelu K, Routray C, Shergill U, O'Hara SP, Faubion W and Shah VH: Endothelial cell toll-like receptor 4 regulates fibrosis-associated angiogenesis in the liver. Hepatology 52: 590-601, 2010.
8. Seki E, de Minicis S, Osterreicher CH, et al: TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 13: 1324-1332, 2007.
9. Endo H, Niioka M, Kobayashi N, Tanaka M and Watanabe T: Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: New insight into the probiotics for the gut-liver axis. PLoS One 8: e63388, 2013.
10. Ruiz AG, Casafont F, Crespo J, et al: Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: Evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg 17: 1374-1380, 2007.
11. Musso G, Gambino R and Cassader M: Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. Curr Opin Lipidol 21: 76-83, 2010.
12. Szabo G, Bala S, Petrasek J and Gattu A: Gut-liver axis and sensing microbes. Dig Dis 28: 737-744, 2010.
13. Nguyen AT, Mandard S, Dray C, et al: Lipopolysaccharides-mediated increase in glucose-stimulated insulin secretion: involvement of the GLP-1 pathway. Diabetes 63: 471-482, 2014.
14. Miele L, Valenza V, La Torre G, et al: Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49: 1877-1887, 2009.
15. Ruberto F, Ianni S, Babetto C, et al: Polymyxin-B endotoxin removal device: making the point on mechanisms of action, clinical effectiveness and possible future applications: review. Infect Disord Drug Targets 13: 128-32, 2013.
16. Yoshiji H, Kuriyama S, Yoshii J, et al: Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34: 745-750, 2001.
17. Kaji K, Yoshiji H, Ikenaka Y, et al: Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. J Gastroenterol 49: 481-491, 2014.
18. Roh YS and Seki E: Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis. J Gastroenterol Hepatol 28: 38-42, 2013.
19. Schumann RR: Old and new findings on lipopolysaccharide-binding protein: a soluble pattern-recognition molecule. Biochem Soc Trans 39: 989-993, 2011.
20. Ulluwishewa D, Anderson RC, McNabb WC, Moughan PJ, Wells JM and Roy NC: Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr 141: 769-776, 2011.
21. Seki E and Schnabl B: Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol 590: 447-458, 2012.
22. Guo S, Al-Sadi R, Said HM and Ma TY: Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14. Am J Pathol 182: 375-387, 2013.
23. Brun P, Castagliuolo I, Di Leo V, et al: Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 292: G518-G525, 2007.
24. Du Plessis J, Vanheel H, Janssen CE, et al: Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function. J Hepatol 58: 1125-1132, 2013.
25. Assimakopoulos SF, Tsamandas AC, Tsiaoussis GI, et al: Intestinal mucosal proliferation, apoptosis and oxidative stress in patients with liver cirrhosis. Ann Hepatol 12: 301-307, 2013.
26. Assimakopoulos SF, Tsamandas AC, Louvros E, et al: Intestinal epithelial cell proliferation, apoptosis and expression of tight junction proteins in patients with obstructive jaundice. Eur J Clin Invest 41: 117-125, 2011.
27. Finamore A, Massimi M, Conti Devirgiliis L and Mengheri E: Zinc deficiency induces membrane barrier damage and increases neutrophil transmigration in Caco-2 cells. J Nutr 138: 1664-1670, 2008.
28. Chiba M, Katayama K, Takeda R, et al: Diuretics aggravate zinc deficiency in patients with liver cirrhosis by increasing zinc excretion in urine. Hepatology Research 43: 365-373, 2013.
29. Mohammad MK, Zhou Z, Cave M, Barve A, McClain CJ. Zinc and liver disease. Nutr Clin Pract 27: 8-20, 2012.
30. De Minicis S, Rychlicki C, Agostinelli L, et al: Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology 59: 1738-1749, 2014.